Valuation : Candel Therapeutics, Inc.

Market Cap 983M 848M 799M 728M 1.36B 92.88B 1.37B 9.46B 3.67B 47.49B 3.69B 3.61B 156B P/E 2026 *
-9.41x
P/E 2027 * -12.1x
Enterprise Value 983M 848M 799M 728M 1.36B 92.88B 1.37B 9.46B 3.67B 47.49B 3.69B 3.61B 156B EV / Sales 2026 *
-
EV / Sales 2027 * 22.7x
Free-Float
85.01%
Yield 2026 *
-
Yield 2027 * -
08-14 BofA Adjusts Price Target on Candel Therapeutics to $12 From $9 MT
08-13 Candel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-13 Candel Therapeutics Q2 Loss Widens MT
08-13 Earnings Flash (CADL) Candel Therapeutics Posts Q2 Net Loss $0.52 a Share, vs. FactSet Est of $0.21 Loss MT
07-13 Stifel Nicolaus Initiates Coverage on Candel Therapeutics With Buy Rating, $22 Price Target MT
06-30 Candel Therapeutics Stock Gains on Launch of Phase 3 Trial for Lung-Cancer Drug DJ
06-30 Candel Therapeutics, Inc. Initiates Global Pivotal Phase 3 Aurora Trial Evaluating Aglatimagene Besadenovec In Advanced Non-Small Cell Lung Cancer Patients With Inadequate Response To Immune Checkpoint Inhibitors CI
06-25 Candel Therapeutics, Inc. Appoints Mark Sims as Chief Commercial Officer, Effective July 6, 2026 CI
06-22 Candel Therapeutics, Inc.(NasdaqGM:CADL) added to S&P Biotechnology Select Industry Index CI
06-02 Candel Therapeutics, Inc. Announces Publication in the Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (Can-2409) in Localized Prostate Cancer CI
05-21 Certain Warrants of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 Certain Stock Options of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI
05-21 54,895,849 Common Stock of Candel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-MAY-2026. CI

Last Transcript : Candel Therapeutics, Inc.

1 day+2.72%
1 week-2.94%
Current month+0.99%
1 month+31.87%
3 months+55.11%
6 months+151.43%
Current year+133.63%
1 week 12.6
Extreme 12.602
14
1 month 9.51
Extreme 9.51
14
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.78
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
17/08/26 Sell

Chief Technology Officer

-7,000 0.0096%
06/07/26 Free

Executive/Senior Manager

285,000 0.3890%
30/06/26 Free

Director

381 0.0005%
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%-2.94%+127.98%+990.91% 983M
+0.97%-1.75%+2.17%+18.46% 49.74B
-0.30%-1.02%+451.04%+496.95% 44.98B
+2.13%+1.70%+38.27%+17.61% 42.52B
+0.87%-3.88%+18.21%+73.17% 40.78B
-0.90%-1.74%+15.20%+48.44% 32.89B
+2.71%+5.66% - - 17.09B
+1.68%-3.43%+24.71%+116.83% 16.28B
+1.70%-1.75%+12.00%+28.50% 14.4B
+3.34%-1.98%+78.65%+39.19% 13.48B
Average +1.49%-2.73%+85.36%+203.34% 27.31B
Weighted average by Cap. +1.02%-2.26%+97.75%+126.59%

Financials

2026 *2027 *
Net sales - 43.38M 37.43M 35.26M 32.12M 60.04M 4.1B 60.49M 417M 162M 2.1B 163M 159M 6.88B
Net income -101M -87.21M -82.15M -74.85M -140M -9.55B -141M -973M -377M -4.88B -380M -371M -16.04B -85.65M -73.89M -69.61M -63.42M -119M -8.09B -119M -824M -320M -4.14B -322M -315M -13.59B
Net Debt - -
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
03/09/26 $13.20 +2.72% 807,198
01/09/26 $12.85 -1.68% 935,641
31/08/26 $13.07 0.00% 895,013
28/08/26 $13.07 -4.95% 1,236,463
27/08/26 $13.75 +3.54% 1,185,355
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
12.85USD
Average target price
21.00USD
Spread / Average Target
+63.42%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CADL Stock